Establishing a Revenue Base for the Scientific Business and Expanding Products and Solutions
First written in FY2016. 17 of 26 entries say "Advanced", first in FY2017. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025Cited as achievedAnnual report
「The Group consists of OLYMPUS CORPORATION (the Company), 81 subsidiaries and 3 affiliates. Its principal business is the manufacture and sale of endoscopes and therapeutic equipment, and it also engages in business activities involving holding companies related to each business and financial investments.」
The business composition after the transfer of the scientific solutions business states that the Group's principal business is the manufacture and sale of endoscopes and therapeutic equipment. - FY2023AchievedAnnual report
「The company completed the transfer on 3 April 2023.」
The scientific solutions business was transferred to エビデント, and the transfer of all shares to Bain Capital was completed. The business was repositioned from one to be expanded within the Company to one pursuing autonomous growth outside the Company. - FY2023-Q2ReframedAnnual report
「We have focused on enhancing the corporate value of the OLYMPUS CORPORATION Group by transferring the scientific solutions business, whose business characteristics differ from those of the medical business, to エビデント and establishing management structures suited to the characteristics of each business, while considering all options, including the transfer of shares in エビデント.」
The positioning of the scientific solutions business was changed from expanding its earnings base and product portfolio within the Company to pursuing autonomous growth through its transfer to エビデント and the transfer of its shares. - FY2023-Q1WorsenedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥21.925 billion, down 11.7% year on year, and an operating loss of ¥1.609 billion, compared with operating income of ¥1.873 billion in the same period of the previous year.」
The Scientific Solutions business posted an 11.7% decline in revenue and swung from operating income in the same period of the previous year to an operating loss. The company cited parts shortages, supply chain disruptions in Shanghai and higher costs associated with strengthening corporate functions after the spin-off. - FY2022AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥119.105 billion, up 24.2% from the previous fiscal year, and operating income of ¥17.526 billion, up 254.1%.」
The Scientific Solutions business recovered from the effects of the COVID-19 pandemic, and its profit base improved through higher revenue and operating income. - FY2022-Q3AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥82.854 billion, up 23.8% year on year, and operating income of ¥11.361 billion, up 284.3%.」
The Scientific Solutions business posted substantial growth in revenue and operating income, driven by the recovery of budget execution in life sciences, expanded sales of biological microscopes in Asia-Pacific and North America, growth in industrial microscopes in China, and growth in nondestructive testing equipment in North America. - FY2022-Q2AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥53.161 billion, up 31.9% year on year, and operating income of ¥6.485 billion, up 2,808.1%.」
The Scientific Solutions business recovered from the effects of the COVID-19 pandemic, with revenue up 31.9% and operating income up 2,808.1%. - FY2022-Q1AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥24.829 billion, up 39.8% year on year, and operating income of ¥1.873 billion, compared with an operating loss of ¥1.604 billion in the same period of the previous year.」
The Scientific Solutions business swung from an operating loss in the same period of the previous year to operating income, while revenue increased 39.8%. The company reported a shift from deterioration to recovery in its profit base. - FY2021WorsenedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥95.861 billion, down 8.9% from the previous fiscal year, and operating income of ¥4.949 billion, down 50.5%.」
The Scientific Solutions business posted lower revenue for FY2021, while operating income also declined 50.5%, resulting in a deterioration of its profit base. - FY2021-Q3WorsenedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥66.941 billion, down 12.7% year on year, and operating income of ¥2.956 billion, down 63.1%.」
The Scientific Solutions business posted lower revenue and operating income for the first 3 quarters cumulatively because of reduced capital investment appetite in the aviation and other industries, restrictions on customer visits, and the postponement or cancellation of business meetings. - FY2021-Q2WorsenedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥40.312 billion, down 19.0% year on year, and operating income of ¥223 million, down 95.9%.」
The Scientific Solutions business’s profit base deteriorated sharply in the first half as the pandemic reduced capital investment appetite in the aviation and other industries and constrained promotional activities. - FY2021-Q1WorsenedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥17.757 billion, down 21.5% year on year, and an operating loss of ¥1.604 billion, compared with operating income of ¥1.644 billion in the same period of the previous year.」
The Scientific Solutions business posted lower revenue as capital investment by the aviation, automotive and other industries declined because of the pandemic and promotional activities were constrained, and it swung from operating income in the same period of the previous year to an operating loss. - FY2020AdvancedAnnual report
「In the Scientific Solutions business, operating income reached a record high as sales of biological microscopes remained firm in all regions and the company pursued greater efficiency in selling, general and administrative expenses.」
The Scientific Solutions business achieved record operating income as biological microscope sales remained firm in all regions and selling, general and administrative expenses became more efficient. - FY2020-Q3AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥76.636 billion, up 4.6% year on year, and operating income of ¥8.009 billion, up 61.5%. Products for hospitals and life sciences research performed well in all regions. Industrial endoscopes remained firm in key markets including aviation and infrastructure, while nondestructive testing equipment increased sales to the North American aviation market and the Chinese and Asian infrastructure markets, resulting in higher revenue.」
The Scientific Solutions business posted higher revenue and operating income, with progress by region and market in hospitals and life sciences, industrial endoscopes and nondestructive testing equipment. - FY2020-Q2AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥49.739 billion, up 5.1% year on year, and operating income of ¥5.38 billion, up 92.1%. Products for hospitals and life sciences research performed well in all regions. Industrial endoscopes remained firm in key markets including aviation and infrastructure, while nondestructive testing equipment increased sales to the North American aviation market and the Chinese and Asian infrastructure markets, resulting in higher revenue.」
The Scientific Solutions business posted higher revenue and operating income, with progress in sales by region and market in hospitals and life sciences, industrial endoscopes and nondestructive testing equipment. - FY2020-Q1AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥22.613 billion, up 7.2% year on year, and operating income of ¥1.644 billion, compared with an operating loss of ¥382 million in the same period of the previous year. Products for hospitals and life sciences research performed well in North America and China. Sales of industrial endoscopes to the aviation and power markets remained strong, while nondestructive testing equipment also increased sales in North America, resulting in higher revenue.」
The Scientific Solutions business posted 7.2% revenue growth and swung from an operating loss to operating income. Products for hospitals and life sciences research in North America and China, industrial endoscopes and nondestructive testing equipment all progressed. - FY2019AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥104.225 billion, up 4.2% from the previous fiscal year, and operating income of ¥8.135 billion, up 26.6%.」
The Scientific Solutions business posted 4.2% revenue growth and 26.6% operating income growth, indicating progress in improving its profit base. - FY2019-Q3AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥73.245 billion, up 4.6% year on year, and operating income of ¥4.958 billion, up 40.9%.」
For the first 3 quarters cumulatively, the Scientific Solutions business posted 4.6% revenue growth and 40.9% operating income growth, indicating progress in improving its profit base. - FY2019-Q2AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥47.304 billion, up 6.0% year on year, and operating income of ¥2.8 billion, up 122.8%.」
The Scientific Solutions business posted 6.0% revenue growth and 122.8% operating income growth in the first half, indicating progress in improving its profit base. - FY2019-Q1AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥21.089 billion, up 5.6% year on year, and an operating loss of ¥382 million, compared with an operating loss of ¥584 million in the same period of the previous year.」
The Scientific Solutions business posted higher revenue, while its operating loss narrowed from ¥584 million in the same period of the previous year to ¥382 million. - FY2018AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥100.016 billion, up 7.1% from the previous fiscal year, and operating income of ¥6.425 billion, up 8.4%.」
The Scientific Solutions business posted higher revenue and operating income for the full fiscal year, and continued to improve its profit base. - FY2018-Q3AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥70.002 billion, up 10.2% year on year, and operating income of ¥3.519 billion, up 88.4%.」
For the first 3 quarters cumulatively, the Scientific Solutions business posted 10.2% revenue growth and 88.4% operating income growth, indicating progress in improving its profit base. - FY2018-Q2AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥44.619 billion, up 10.5% year on year, and operating income of ¥1.257 billion, compared with an operating loss of ¥199 million in the same period of the previous year.」
The Scientific Solutions business posted 10.5% revenue growth in the first half and swung from an operating loss in the same period of the previous year to operating income. - FY2018-Q1AdvancedAnnual report
「The Scientific Solutions business recorded consolidated revenue of ¥19.973 billion, up 7.3% year on year, and an operating loss of ¥584 million, compared with an operating loss of ¥1.068 billion in the same period of the previous year.」
The Scientific Solutions business posted 7.3% year-on-year revenue growth, while its operating loss narrowed from ¥1.068 billion to ¥584 million. - FY2017AdvancedAnnual report
「Revenue in the Scientific Solutions business declined because of yen appreciation, but increased 1% year on year on a local-currency basis excluding the effect of foreign exchange. Products for hospitals and life sciences research posted lower sales in Europe because of budget cuts and delays in budget execution, while performance remained firm in Japan, the United States and Asia. Sales of industrial microscopes to universities and research institutions remained sluggish, but nondestructive testing equipment performed steadily, supported by the recovery in resource prices from the second half onward.」
Regarding the Scientific Solutions business, the company reported higher local-currency revenue and progress by region and product, indicating progress in expanding its product and solution portfolio. - FY2016First statedAnnual report
「In the Scientific Solutions business, we will establish a profit base by pursuing strategies tailored to customer groups and aim to expand our product and solution portfolio.」
The policy is to link the shift in strategy from product categories to customer groups with the establishment of a profit base and portfolio expansion.